LXEO (Lexeo Therapeutics) Inventory Turnover: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LXEO Lexeo Therapeutics Inc LXEO
12 GF Score
Price $4.08
! 3 Warning Signs
View Full Analysis

What is Lexeo Therapeutics Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Lexeo Therapeutics's Cost of Goods Sold for the three months ended in Jun. 2026 was $0.56 Mil. Lexeo Therapeutics's Average Total Inventories for the quarter that ended in Jun. 2026 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Lexeo Therapeutics's Days Inventory for the three months ended in Jun. 2026 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lexeo Therapeutics  (NAS:LXEO) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Lexeo Therapeutics's Days Inventory for the three months ended in Jun. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Jun. 2026 )/Cost of Goods Sold (Q: Jun. 2026 )*Days in Period
=0/0.556*365 / 4
=0.00

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lexeo Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2026 ) / Revenue (Q: Jun. 2026 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Lexeo Therapeutics Inventory Turnover Related Terms

Lexeo Therapeutics Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Lexeo Therapeutics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexeo Therapeutics Inventory Turnover Chart

Lexeo Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventory Turnover
Get a 7-Day Free Trial - - - - -

Lexeo Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
LXEO
12GF Score
Lexeo Therapeutics Inc LXEO
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexeo Therapeutics Inventory Turnover Calculation

Lexeo Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Inventory Turnover (A: Dec. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2025 ) / ((Total Inventories (A: Dec. 2024 ) + Total Inventories (A: Dec. 2025 )) / count )
=2.079 / ((0 + 0) / 1 )
=2.079 / 0
=N/A

Lexeo Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover (Q: Jun. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Jun. 2026 ) / ((Total Inventories (Q: Mar. 2026 ) + Total Inventories (Q: Jun. 2026 )) / count )
=0.556 / ((0 + 0) / 1 )
=0.556 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexeo Therapeutics Business Description

Address 345 Park Avenue South, Floor 6, New York, NY, USA, 10010
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
12GF Score

Get the complete analysis for LXEO

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.08
Price